Report Detail
Global Etoricoxib Intermediate Market Insights, Forecast to 2025
- RnM3515297 |
- 11 June, 2019 |
- Global |
- 117 Pages |
- QYResearch |
- Pharma & Healthcare
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that explicitly targets enzymes responsible for inflammation and pain namely cyclooxygenase-2 and COX-2.
Some of the NSAIDs can be used in a single dose to treat various types of pain; it can also be used for post-surgical pains.
The global Etoricoxib Intermediate market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Etoricoxib Intermediate market based on company, product type, end user and key regions.
This report studies the global market size of Etoricoxib Intermediate in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Etoricoxib Intermediate in these regions.
This research report categorizes the global Etoricoxib Intermediate market by top players/brands, region, type and end user. This report also studies the global Etoricoxib Intermediate market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Bayer
Novacap
Abbott
Pfizer
Geri-Care
Perrigo
Kopran
Merck
Sun Pharmaceutical
GlaxoSmithKline
Market size by Product
n-House Manufacturing
Contract Manufacturing Organizations
Market size by End User
Rheumatoid Arthritis
Psoriatic Arthritis
Osteoarthritis
Ankylosing Spondylitis
Chronic Low Back Pain
Acute Pain
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Etoricoxib Intermediate market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Etoricoxib Intermediate market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Etoricoxib Intermediate companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Etoricoxib Intermediate submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Etoricoxib Intermediate are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Etoricoxib Intermediate market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Etoricoxib Intermediate Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Etoricoxib Intermediate Market Size Growth Rate by Product
- 1.4.2 n-House Manufacturing
- 1.4.3 Contract Manufacturing Organizations
- 1.5 Market by End User
- 1.5.1 Global Etoricoxib Intermediate Market Size Growth Rate by End User
- 1.5.2 Rheumatoid Arthritis
- 1.5.3 Psoriatic Arthritis
- 1.5.4 Osteoarthritis
- 1.5.5 Ankylosing Spondylitis
- 1.5.6 Chronic Low Back Pain
- 1.5.7 Acute Pain
- 1.5.8 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Etoricoxib Intermediate Market Size
- 2.1.1 Global Etoricoxib Intermediate Revenue 2014-2025
- 2.1.2 Global Etoricoxib Intermediate Sales 2014-2025
- 2.2 Etoricoxib Intermediate Growth Rate by Regions
- 2.2.1 Global Etoricoxib Intermediate Sales by Regions
- 2.2.2 Global Etoricoxib Intermediate Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Etoricoxib Intermediate Sales by Manufacturers
- 3.1.1 Etoricoxib Intermediate Sales by Manufacturers
- 3.1.2 Etoricoxib Intermediate Sales Market Share by Manufacturers
- 3.1.3 Global Etoricoxib Intermediate Market Concentration Ratio (CR5 and HHI)
- 3.2 Etoricoxib Intermediate Revenue by Manufacturers
- 3.2.1 Etoricoxib Intermediate Revenue by Manufacturers (2014-2019)
- 3.2.2 Etoricoxib Intermediate Revenue Share by Manufacturers (2014-2019)
- 3.3 Etoricoxib Intermediate Price by Manufacturers
- 3.4 Etoricoxib Intermediate Manufacturing Base Distribution, Product Types
- 3.4.1 Etoricoxib Intermediate Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Etoricoxib Intermediate Product Type
- 3.4.3 Date of International Manufacturers Enter into Etoricoxib Intermediate Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Etoricoxib Intermediate Sales by Product
- 4.2 Global Etoricoxib Intermediate Revenue by Product
- 4.3 Etoricoxib Intermediate Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Etoricoxib Intermediate Breakdown Data by End User
6 North America
- 6.1 North America Etoricoxib Intermediate by Countries
- 6.1.1 North America Etoricoxib Intermediate Sales by Countries
- 6.1.2 North America Etoricoxib Intermediate Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Etoricoxib Intermediate by Product
- 6.3 North America Etoricoxib Intermediate by End User
7 Europe
- 7.1 Europe Etoricoxib Intermediate by Countries
- 7.1.1 Europe Etoricoxib Intermediate Sales by Countries
- 7.1.2 Europe Etoricoxib Intermediate Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Etoricoxib Intermediate by Product
- 7.3 Europe Etoricoxib Intermediate by End User
8 Asia Pacific
- 8.1 Asia Pacific Etoricoxib Intermediate by Countries
- 8.1.1 Asia Pacific Etoricoxib Intermediate Sales by Countries
- 8.1.2 Asia Pacific Etoricoxib Intermediate Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Etoricoxib Intermediate by Product
- 8.3 Asia Pacific Etoricoxib Intermediate by End User
9 Central & South America
- 9.1 Central & South America Etoricoxib Intermediate by Countries
- 9.1.1 Central & South America Etoricoxib Intermediate Sales by Countries
- 9.1.2 Central & South America Etoricoxib Intermediate Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Etoricoxib Intermediate by Product
- 9.3 Central & South America Etoricoxib Intermediate by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Etoricoxib Intermediate by Countries
- 10.1.1 Middle East and Africa Etoricoxib Intermediate Sales by Countries
- 10.1.2 Middle East and Africa Etoricoxib Intermediate Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Etoricoxib Intermediate by Product
- 10.3 Middle East and Africa Etoricoxib Intermediate by End User
11 Company Profiles
- 11.1 Bayer
- 11.1.1 Bayer Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Bayer Etoricoxib Intermediate Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Bayer Etoricoxib Intermediate Products Offered
- 11.1.5 Bayer Recent Development
- 11.2 Novacap
- 11.2.1 Novacap Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Novacap Etoricoxib Intermediate Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Novacap Etoricoxib Intermediate Products Offered
- 11.2.5 Novacap Recent Development
- 11.3 Abbott
- 11.3.1 Abbott Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Abbott Etoricoxib Intermediate Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Abbott Etoricoxib Intermediate Products Offered
- 11.3.5 Abbott Recent Development
- 11.4 Pfizer
- 11.4.1 Pfizer Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Pfizer Etoricoxib Intermediate Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Pfizer Etoricoxib Intermediate Products Offered
- 11.4.5 Pfizer Recent Development
- 11.5 Geri-Care
- 11.5.1 Geri-Care Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Geri-Care Etoricoxib Intermediate Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Geri-Care Etoricoxib Intermediate Products Offered
- 11.5.5 Geri-Care Recent Development
- 11.6 Perrigo
- 11.6.1 Perrigo Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Perrigo Etoricoxib Intermediate Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Perrigo Etoricoxib Intermediate Products Offered
- 11.6.5 Perrigo Recent Development
- 11.7 Kopran
- 11.7.1 Kopran Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Kopran Etoricoxib Intermediate Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Kopran Etoricoxib Intermediate Products Offered
- 11.7.5 Kopran Recent Development
- 11.8 Merck
- 11.8.1 Merck Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Merck Etoricoxib Intermediate Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Merck Etoricoxib Intermediate Products Offered
- 11.8.5 Merck Recent Development
- 11.9 Sun Pharmaceutical
- 11.9.1 Sun Pharmaceutical Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Sun Pharmaceutical Etoricoxib Intermediate Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Sun Pharmaceutical Etoricoxib Intermediate Products Offered
- 11.9.5 Sun Pharmaceutical Recent Development
- 11.10 GlaxoSmithKline
- 11.10.1 GlaxoSmithKline Company Details
- 11.10.2 Company Business Overview
- 11.10.3 GlaxoSmithKline Etoricoxib Intermediate Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 GlaxoSmithKline Etoricoxib Intermediate Products Offered
- 11.10.5 GlaxoSmithKline Recent Development
12 Future Forecast
- 12.1 Etoricoxib Intermediate Market Forecast by Regions
- 12.1.1 Global Etoricoxib Intermediate Sales Forecast by Regions 2019-2025
- 12.1.2 Global Etoricoxib Intermediate Revenue Forecast by Regions 2019-2025
- 12.2 Etoricoxib Intermediate Market Forecast by Product
- 12.2.1 Global Etoricoxib Intermediate Sales Forecast by Product 2019-2025
- 12.2.2 Global Etoricoxib Intermediate Revenue Forecast by Product 2019-2025
- 12.3 Etoricoxib Intermediate Market Forecast by End User
- 12.4 North America Etoricoxib Intermediate Forecast
- 12.5 Europe Etoricoxib Intermediate Forecast
- 12.6 Asia Pacific Etoricoxib Intermediate Forecast
- 12.7 Central & South America Etoricoxib Intermediate Forecast
- 12.8 Middle East and Africa Etoricoxib Intermediate Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Etoricoxib Intermediate Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Etoricoxib Intermediate . Industry analysis & Market Report on Etoricoxib Intermediate is a syndicated market report, published as Global Etoricoxib Intermediate Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Etoricoxib Intermediate market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
